Current evidence is scanty on efficacy of BRAF or MEK inhibition in treating BRAF G469‐mutant NSCLC, coming mostly from isolated cases and preclinical models.4, 16, 17. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.